RT Journal Article
SR Electronic
T1 Genetics of symptom remission in outpatients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.24.21252396
DO 10.1101/2021.02.24.21252396
A1 Dubé, Marie-Pierre
A1 Lemaçon, Audrey
A1 Barhdadi, Amina
A1 Perreault, Louis-Philippe Lemieux
A1 Oussaïd, Essaïd
A1 Asselin, Géraldine
A1 Provost, Sylvie
A1 Sun, Maxine
A1 Sandoval, Johanna
A1 Legault, Marc-André
A1 Mongrain, Ian
A1 Dubois, Anick
A1 Valois, Diane
A1 Dedelis, Emma
A1 Lousky, Jennifer
A1 Choi, Julie
A1 Goulet, Elisabeth
A1 Savard, Christiane
A1 Chicoine, Lea-Mei
A1 Cossette, Mariève
A1 Chabot-Blanchet, Malorie
A1 Guertin, Marie-Claude
A1 de Denus, Simon
A1 Bouabdallaoui, Nadia
A1 Marchand, Richard
A1 Bassevitch, Zohar
A1 Nozza, Anna
A1 Gaudet, Daniel
A1 L’Allier, Philippe L
A1 Hussin, Julie
A1 Boivin, Guy
A1 Busseuil, David
A1 Tardif, Jean-Claude
YR 2021
UL http://medrxiv.org/content/early/2021/03/01/2021.02.24.21252396.abstract
AB We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; P = 4.94 × 10−8) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. In 851 participants not treated with colchicine (placebo), there was a significant association at 9q33.1 (rs62575331; P = 2.95 × 10−8) in interaction with colchicine (P = 1.19 × 10−5) without impact on risk of hospitalisations, highlighting a possibly shared mechanistic pathway. By day 15 of the study, 46%, 62% and 64% of those with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. The findings need to be replicated and could contribute to the biological understanding of COVID-19 symptom remission.Competing Interest StatementMPD reports personal fees and other from Dalcor Pharmaceuticals and personal fees from GlaxoSmithKline, other from AstraZeneca, Pfizer, Servier, Sanofi. MPD and JCT have a patent "Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events" issued to Dalcor, no royalties received, a patent "Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent" issued to Dalcor, no royalties received, and a patent "Methods for using low dose colchicine after myocardial infarction" with royalties paid to the Montreal Heart Institute. JCT reports grants from the Government of Quebec, the Montreal Heart Institute Foundation, the Bill and Melinda Gates Foundation, Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Pfizer, RegenXBio and Sanofi; personal fees from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals, Pfizer, Pharmascience, Sanofi and Servier; and minor equity interest from Dalcor Pharmaceuticals. In addition, JCT's institution has submitted a patent "Methods of treating a coronavirus infection using Colchicine" pending and a patent "Early administration of low-dose colchicine after myocardial infarction" pending. JCT has waived his rights in all patents related to colchicine and does not stand to benefit financially if colchicine becomes used as a treatment for COVID-19. NB reports personal fees from AstraZeneca outside of the present work. SdD was supported through grants from AstraZeneca, Pfizer, Roche Molecular Science, Dalcor Pharmaceuticals outside of the present work. JH is funded by an IVADO COVID-19 fast response grant with co-applicant MPD and JCT (CVD19-030). Other authors have nothing to declare.Clinical TrialNCT04322682Funding StatementThe genetic study of COLCORONA was funded in part by the Government of Quebec, the Bill and Melinda Gates Foundation, the Health Collaboration Acceleration Fund (FACS) from the Government of Quebec, and philanthropist Sophie Desmarais. Pharmascience provided the study medication in the COLCORONA trial. The funding sources had no role in the design or conduct of the study, or the preparation or review of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Montreal Heart Institute research ethics committee and complies with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe anonymized patient level data from the COLCORONA trial will be shared via the Vivli (vivli.org) data repository. The patient level genetic data underlying this article cannot be shared to preserve the privacy of study participants. Summary statistics from the GWAS results are available for download and visualisation via PheWeb at statgen.org/pheweb/colcorona. http://statgen.org/pheweb/colcorona CIConfidence intervalCOLCORONACOLchicine CORONAvirus SARS-CoV-2 trialCOVID-19Coronavirus disease of 2019eQTLexpression Quantitative Trait LociGWASGenome-Wide Association StudyHRHazard RatiolncRNALong non-coding RNAMAFMinor allele frequencyOROdds ratio